Clinical experience with CMN-005

Allogeneic Phase 1/2a CARCIK-CD19 (CMN-005) dose escalation Clinical Trial***

  • IST trial conducted at 2 sites in Italy
  • Adult and pediatric patients with B-cell precursor ALL who are either chemo-refractory or relapsed after allogeneic HSCT
  • 4 pediatric/17 adult patients treated
  • All patients progressing at time of enrollment
  • Single infusion after lymphodepletion
  • N=27 evaluable patients

Interim Results

  • Phase 1/2a dose escalation (Final data presented at ASH 2022)
  • 27 evaluable patients (n=21 at 2 highest dose levels)
  • 4 pediatric; 23 adults
  • Little to no toxicity observed
  • 30% of patients alive at ~3 years of follow-up

***J Clin Invest. (2020) 130(11):6021


CR rate 28 days post-infusion at 2 highest doses N=12

Of CRs minimal residual disease negative

Serious adverse events
Dose limiting toxicities

GVHD, Neurotoxicity